Reading view
STAT+: Patient health data as a public utility: A former ARPA-H data chief explains
Last year, the Department of Health and Human Services published a sweeping document that described the agencyβs approach to real-world data. Historically, health and biomedical data has been intentionally manufactured, the output of carefully designed clinical trials. But in a digitized world, it can instead be mined β and patientsβ interactions with the health care system are the natural resource.
The Living HHS Open Data Plan, published in July, proposed treating data more like we do other natural resources. βAt the coreβ of the plan, it reads, βlies the concept that data is a βpublic utilityβ for good that powers scientific advancement, innovation, and progress.β Patients should have access to that utility, HHS argued, but it should also be easier to leverage for research, safety monitoring, and other uses in the public interest.Β
On Thursday, a group of researchers, former agency officials, and health data companies continued that call in a policy forum published in Science. If health data is to be treated like a public utility, they write, it should be similarly governed. Like electricity, the system would have to involve customers, local distribution companies, transmission companies, generators, and the government.Β
Continue to STAT+ to read the full storyβ¦


Β© Adobe
Genomically Matched Cancer Therapies Only as Good as Supporting Evidence
(MedPage Today) -- Patients with advanced/refractory cancers treated with genomically matched therapies had better overall survival only when the treatments had support from prospective studies, a large multicenter cohort study from Australia showed... Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model
MedComm (2020). 2026 Mar 2;7(3):e70656. doi: 10.1002/mco2.70656. eCollection 2026 Mar.
ABSTRACT
Chemotherapy is the mainstay in the treatment of advanced gastric cancer (GC); yet, GC showed diverse responses to first-line chemotherapy regimens and the underlying molecular basis is still not clear. Here, we established a system that combined organoid-based chemotherapy regimen screening and transcriptome-based evaluation to identify underlying molecular signatures of different responses to chemotherapy. We generated 19 GC patient-derived organoids (PDOs) from surgically resected specimens with corresponding histological characteristics of parent tumors and tested all of the five most commonly used first-line chemotherapy regimens. Based on the treatment responses, PDOs were classified into double-sensitive, single-sensitive, and not-sensitive groups. PDOs that responded well to chemotherapy presented high expression levels of the P53 pathway genes and low expression levels of cell proliferative activity genes. Furthermore, the chemotherapy-based tumor classification of GC was established. The GC tumor classification was verified by multi-omics features from the TCGA dataset and public drug response datasets. In conclusion, this study systematically evaluated clinical chemotherapy regimens for GC and identified chemotherapy response-associated molecular signatures based on human GC organoids, which are beneficial to the precise treatments of GC.
PMID:41782964 | PMC:PMC12954136 | DOI:10.1002/mco2.70656